Registered outcomes20

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 20

List	Outcome	Time frame	Description
Primary	Ratio of Absolute Neutrophil Count at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Primary	Ratio of the Percentage Neutrophil Count at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Primary	24-hour Sputum Weight(g)	Baseline and day 28	Sputum weight (g) collected during 24 hour periods.Change from Baseline to day 28
Primary	Slow Vital Capacity (SVC)	Baseline and day 28	Slow Vital Capacity (L) as a measure of lung function.Change from baseline to day 28
Primary	Forced Expiratory Volume in 1 Second (FEV1)	Baseline and day 28	Forced Expiratory Volume in 1 Second (L) as a measure of lung function.Change from baseline to day 28
Primary	Forced Vital Capacity (FVC)	Baseline and day 28	Forced Vital Capacity (L) as a measure of lung function.Change from baseline to day 28
Primary	Forced Expiratory Flow Between 25 and 75% of Forced Vital Capacity (FEF25-75%)	Baseline and day 28	FEF25-75% as a measure of lung function.Change from baseline to day 28
Primary	Morning Peak Expiratory Flow (PEF)	Last 7 days on treatment	Morning Peak Expiratory Flow (L/min) as a measure of lung function.Change from mean baseline value to mean of the last 7 days on treatment
Primary	Evening Peak Expiratory Flow (PEF)	Last 7 days on treatment	Evening Peak Expiratory Flow (L/min) as a measure of lung function.Change from mean baseline value to mean of the last 7 days on treatment
Primary	Bronkotest Diary Card Signs and Symptoms	Last 7 days on treatment	The Bronkotest diary card includes 8 questions on signs and symptoms. Symptom scores were recorded for night-time symptoms, breathing, sputum colour, sputum amount, sputum type, wellbeing, and cough, generally scored on a scale from 0 (no symptoms) to 4 (worst symptoms). ANOVA models were fitted to compare the change from baseline between AZD9668 and placebo for each question separately, with a p-value of 0.1 considered statistically significant. The number of number of these 8 measures with significant differences is reported.
Primary	St George's Respiratory Questionnaire for COPD Patients (SGRQ-C)	Baseline and day 28	SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). Change from baseline to day 28.
Secondary	Ratio of Tumour Necrosis Factor Alpha (TNF α) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Interleukin 6 (IL-6) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Interleukin 1 Beta (IL-1β) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Monocyte Chemoattractant Protein-1 (MCP-1) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Interleukin 8 (IL-8) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Leukotriene B4 (LTB4) at End of Treatment Compared to Baseline	End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.	Ratio of the mean of 3 visits at the end of the treatment period to the mean of the 3 baseline visits
Secondary	Ratio of Urine Desmosine (Free) (Normalised for Creatinine) at End of Treatment Compared to Baseline	Baseline and day 28	Ratio of day 28 to baseline
Secondary	Ratio of Urine Desmosine (Total) (Normalised for Creatinine) at End of Treatment Compared to Baseline	Baseline and day 28	Ratio of day 28 to baseline

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00769119/registered

API reference For AI assistants